Search

Your search keyword '"Peter W. Laird"' showing total 379 results

Search Constraints

Start Over You searched for: Author "Peter W. Laird" Remove constraint Author: "Peter W. Laird"
379 results on '"Peter W. Laird"'

Search Results

1. Comprehensive evaluation of the Infinium human MethylationEPIC v2 BeadChip

3. Analysis of germline-driven ancestry-associated gene expression in cancers

4. Analytical protocol to identify local ancestry-associated molecular features in cancer

5. Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway

6. Integrated Molecular Characterization of Testicular Germ Cell Tumors

7. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence

8. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles

9. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

10. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

11. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

12. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

13. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

14. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

15. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

16. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

17. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

18. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

19. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

20. Microcell-Mediated Chromosome Transfer Identifies EPB41L3 as a Functional Suppressor of Epithelial Ovarian Cancers

21. Rapid and quantitative method of allele-specific DNA methylation analysis

22. DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer

24. Data from DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer

26. Evaluating The Infinium Human MethylationEPIC v2 BeadChip

28. Table S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

30. Data from Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice

31. Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

33. Supplementary Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

34. Supplementary Table 3 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

35. Data from High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

36. Data from DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic Associations

37. Supplementary Figure from High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

38. Data from Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History

39. Supplementary Table and Figure Legends from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

40. Supplementary Figure 3 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

41. Supplementary Figure 1 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

42. Data from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

43. Supplementary Data from High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

44. Supplementary Figure 5 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

45. Supplementary Table from High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

46. Supplemental Table 1 from Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History

47. Supplementary Figure 2 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

49. Supplementary Table 1 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

50. Supplementary Table 2 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

Catalog

Books, media, physical & digital resources